Ion Pump Design for Improved Pumping Speed at Low Pressure

Paolini, Chiara,Audi, Mauro,Denning, Mark The Korean Vacuum Society 2016 Applied Science and Convergence Technology Vol.25 No.6

Even if ion pumps are widely and mostly used in ultra-high vacuum (UHV) conditions, virtually every existing ion pump has its maximum pumping speed around 1E-6 mbar (1E-4 Pa). Discharge intensity in the ion pump Penning cell is defined as the current divided by pressure (I/P). This quantity reflects the rate of cathode bombardment by ions, which underlies all of the various pumping mechanisms that occur in ion pumps (chemisorption on sputtered material, ion burial, etc.), and therefore is an indication of pumping speed. A study has been performed to evaluate the influence of magnetic fields and cell dimensions on the ion pump discharge intensity and consequently on the pumping speed at different pressures. As a result, a combination of parameters has been developed in order to design and build an ion pump with the pumping speed peak shifted towards lower pressures. Experimental results with several different test set-ups are presented and a prototype of a new 200 l/s ion pump with the maximum pumping speed in the 1E-8 mbar (1E-6 Pa) is described. A model of the system has also been developed to provide a framework for understanding the experimental observations.

Ion Pump Design for Improved Pumping Speed at Low Pressure

Chiara Paolini,Mauro Audi,Mark Denning 한국진공학회 2016 Applied Science and Convergence Technology Vol.25 No.6

Even if ion pumps are widely and mostly used in ultra-high vacuum (UHV) conditions, virtually every existing ion pump has its maximum pumping speed around 1E-6 mbar (1E-4 Pa). Discharge intensity in the ion pump Penning cell is defined as the current divided by pressure . This quantity reflects the rate of cathode bombardment by ions, which underlies all of the various pumping mechanisms that occur in ion pumps (chemisorption on sputtered material, ion burial, etc.), and therefore is an indication of pumping speed. A study has been performed to evaluate the influence of magnetic fields and cell dimensions on the ion pump discharge intensity and consequently on the pumping speed at different pressures. As a result, a combination of parameters has been developed in order to design and build an ion pump with the pumping speed peak shifted towards lower pressures. Experimental results with several different test set-ups are presented and a prototype of a new 200 l/s ion pump with the maximum pumping speed in the 1E-8 mbar (1E-6 Pa) is described. A model of the system has also been developed to provide a framework for understanding the experimental observations.

Ion pump design for improved pumping speed at low pressure

Chiara PAOLINI,Mauro AUDI,Mark DENNING 한국진공학회 2016 한국진공학회 학술발표회초록집 Vol.2016 No.8

Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia

Giorgio Bogani,Antonino Ditto,Stefano Ferla,Biagio Paolini,Claudia Lombardo,Domenica Lorusso,Francesco Raspagliesi 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.2

Objective: We have investigated outcomes of women presenting with recurrent high-grade vaginal intra-epithelial neoplasia. Methods: Data of consecutive women diagnosed with recurrent high-grade vaginal intraepithelial neoplasia after primary treatment(s) were retrieved. Risk of developing new recurrence over the time was assessed using Kaplan-Meier and Cox models. Results: Data of 117 women were available for the analysis. At primary diagnosis, 41 (35%), 4 (3.4%) and 72 (61.6%) patients had had laser, pure surgical and medical treatments, respectively. Secondary treatments included: laser ablation and medical treatment in 95 (81.2%) and 22 (18.8%) cases, respectively. After a mean (standard deviation) follow-up of 72.3 (±39.5) months, 37 (31.6%) out of the entire cohort of 117 patients developed a second recurrence. Median time to recurrence was 20 (range, 5–42) months. Patients with recurrent high-grade vaginal intra-epithelial neoplasia undergoing medical treatments were at higher risk of developing a second recurrence in comparison to women having laser treatment (p=0.013, log-rank test). After we corrected our results for type of treatment used for recurrent disease, we observed that the execution of primary laser treatment was independently associated with a lower risk of developing new recurrences (hazard ratio [HR]=0.46; 95% confidence interval [CI]=0.21–0.99; p=0.050). The other variable that is independently associated with a new recurrence is the persistent infection from HPV16 or 18 (HR=3.87; 95% CI=1.15–13.0; p=0.028). Conclusion: Patients with recurrent high-grade vaginal intra-epithelial neoplasia are at high risk of developing new recurrences. Our data underline that the choice of primary treatment might have an impact of further outcomes.

The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer

Giorgio Bogani,Umberto Leone Roberti Maggiore,Biagio Paolini,Antonino Diito,Fabio Martinelli,Domenica Lorusso,Francesco Raspagliesi 대한부인종양학회 2019 Journal of Gynecologic Oncology Vol.30 No.1

Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) >1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16–6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29–7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29–1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12–7.74; p=0.027) were independently associated with an improved overall survival. Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.

In vitro Antifungal Activity and Chemical Composition of Warionia saharae Essential Oil against 3 Apple Phytopathogenic Fungi

Mohamed Znini,Gregory Cristofari,Lhou Majidi,Abdelhay El Harrak,Julien Paolini,Jean Costa 한국식품과학회 2013 Food Science and Biotechnology Vol.22 No.suppl1

Essential oil of aerial parts of Warionia saharae was obtained by hydrodistillation and analyzed by GC and GC-MS. Thirty-nine compounds were identified, accounting for 93.2% of the total oil. β-Eudesmol (34.9%), nerolidol-E (23%), and linalool (15.2%) were the most abundant components. The antifungal activity of the W. saharae oil was tested by poisoned food (PF) technique and the volatile activity (VA) assay against 3 phytopathogenic causing the deterioration for apple. The results indicated that the W. saharae oil inhibited significantly the mycelial growth of all strains tested (p<0.05). The minimum inhibitory concentration against Alternaria sp. was 2 μL/mL air in VA assay, whereas >2 μL/mL in PF technique for all strains. Fungal spore production was completely inhibited at 1 μL/mL air for Alternaria sp. and at 2 μL/mL air for Penicillium expansum and Rhizopus stolonifer.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio,김동완,Yi-Long Wu,Kazuhiko Nakagawa,Benjamin J. Solomon,Alice T. Shaw,Satoshi Hashigaki,Emiko Ohki,Tiziana Usari,Jolanda Paolini,Anna Polli,Keith D. Wilner,Tony Mok 대한암학회 2018 Cancer Research and Treatment Vol.50 No.3

Purpose Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. Materials and Methods This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively. Results In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade) with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. Conclusion These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.